SoftOx Infection remover - US Department of Defense (DoD) grant
SoftOx, today announced the US Department of Defense (DoD) awarded SoftOx $1.977 million (USD) for research and development of the SoftOx Infection remover (Biofilm Eradicator).
Oslo 03.11.2020
The project is a research and development collaboration between SoftOx Solutions AS and leading US and European wound care clinics, focusing on chronic wounds and biofilm infections. The project represents an innovative treatment principle in how to prevent and treat biofilm infections in wounds. The grant will contribute to perform clinical investigations to evaluate the SoftOx technology in humans with serious non-healing wounds.
The award was issued on behalf of the Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) a biomedical technology consortium that collaborates under a transaction agreement (OTA) with the US Army Medical Research and Development Command (USAMRDC). The award issued is entitled “Clinical Development of a New Antimicrobial Agent to Treat and Prevent Biofilm Formation in Wounds”. SoftOx considers it a great honor that one of the world’s leading research organizations supports the development and the technology of SoftOx by issuing the award.
About SoftOx Solutions
SoftOx Solutions AS (SoftOx, listed at Oslo Stock Exchange Merkur Market) is a Norwegian MedTech company based in Oslo with the aim to contribute to fight major threats to human health, namely; the Emergence of Antimicrobial Resistance (AMR), Biofilm Infections in Chronic Wounds and Spread of viruses. For more information about SoftOx please visit www.soft-ox.com
About Medical Technology Enterprise Consortium
MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command. To find out more about MTEC, visit www.mtec-sc.org.
Oslo 03.11.2020
The project is a research and development collaboration between SoftOx Solutions AS and leading US and European wound care clinics, focusing on chronic wounds and biofilm infections. The project represents an innovative treatment principle in how to prevent and treat biofilm infections in wounds. The grant will contribute to perform clinical investigations to evaluate the SoftOx technology in humans with serious non-healing wounds.
The award was issued on behalf of the Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) a biomedical technology consortium that collaborates under a transaction agreement (OTA) with the US Army Medical Research and Development Command (USAMRDC). The award issued is entitled “Clinical Development of a New Antimicrobial Agent to Treat and Prevent Biofilm Formation in Wounds”. SoftOx considers it a great honor that one of the world’s leading research organizations supports the development and the technology of SoftOx by issuing the award.
About SoftOx Solutions
SoftOx Solutions AS (SoftOx, listed at Oslo Stock Exchange Merkur Market) is a Norwegian MedTech company based in Oslo with the aim to contribute to fight major threats to human health, namely; the Emergence of Antimicrobial Resistance (AMR), Biofilm Infections in Chronic Wounds and Spread of viruses. For more information about SoftOx please visit www.soft-ox.com
About Medical Technology Enterprise Consortium
MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command. To find out more about MTEC, visit www.mtec-sc.org.
